Incidence and risk factors of nephritis in childhood Henoch-Schonlein purpura

Keywords: Henoch-Schönlein purpura; nephritis; childhood; risk factors


Background Henoch-Schönlein Purpura (HSP) is the most common systemic vasculitis disease in children. It is characterized by involvement of the skin, joints, gastrointestinal tract, and kidney. Kidney manifestations may progress to severe nephritis, even lead to end-stage kidney disease.

Objective To identify the incidence and risk factors of nephritis in childhood HSP.

Methods A retrospective cohort study was performed to evaluate clinical, demographic, laboratory, and therapeutic parameters of HSP patients aged 0-18 years between 2011-2019 at Dr. Cipto Mangunkusumo Hospital, Jakarta. Diagnoses of HSP were made according to the 2008 EULAR/PRES/PRINTO criteria. We
followed subjects’ medical records for at least 3 months after disease onset to observe incidence and risk factors of Henoch-Schönlein nephritis (HSN).
Results There were 112 HSP patients (aged 2-17 years) included in this study. HSN was found in 40 out of 112 patients (35.7%). Nephritis developed within the first 4 weeks for a majority of cases. Multivariate analysis showed that persistent purpura (OR 3.306; 95%CI 1.315 to 8.315; P=0.011) and acute phase leukocytosis
(OR 2.585; 95%CI 1.047 to 6.385; P=0.039) were significantly associated risk factors for HSN. We found that corticosteroid use did not reduce the risk of HSN. The accumulation of several risk factors was associated with the likelihood of developing HSN.

Conclusion Persistent purpura and acute phase leukocytosis are independent risk factors for HSN. Therefore, blood tests are needed to estimate the risk of HSN. Early corticosteroid therapy do not reduce the risk of kidney impairment.


1. Lau KK, Suzuki H, Novak J, Wyatt RJ. Pathogenesis of Henoch-Schönlein purpura nephritis. Pediatr Nephrol. 2010;25:19-26. DOI:
2. Chen JY, Mao JH. Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management. World J Pediatr. 2015;11:29-34. DOI:
3. Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010;69:798-806. DOI:
4. Davin JC, Coppo R. Henoch-Schönlein purpura nephritis in children. Nat Rev Nephrol. 2014;10(10):563-73. DOI:
5. Kawasaki Y, Ono A, Ohara S, Suzuki Y, Suyama K, Suzuki J, et al. Henoch-Schönlein purpura nephritis in childhood: pathogenesis, prognostic factors and treatment. Fukushima J Med Sci. 2013;59:15-26. DOI:
6. Saulsbury FT. Clinical update: Henoch-Schönlein purpura. Lancet. 2007;369:976-8. DOI:
7. Gardner-Medwin JMM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360:1197-202. DOI:
8. Stewart M, Savage JM, Bell B, McCord B. Long term renal prognosis of Henoch-Schönlein Purpura in an unselected childhood population. Eur J Pediatr. 1988;147:113-5. DOI:
9. Sano H, Izumida M, Shimizu H, Ogawa Y. Risk factors of kidney involvement and significant proteinuria in Henoch-Schönlein purpura. Eur J Pediatr. 2002;161:196-201. DOI:
10. Shin JI, Park JM, Shin YH, Hwang DH, Kim JH, Lee JS. Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schönlein purpura. Scand J Rheumatol. 2006;35:56-60. DOI:
11. Kaku Y, Nohara K, Honda S. Kidney involvement in Henoch-Schonlein purpura: a multivariate analysis of prognostic factors. Kidney Int. 1998;53:1755-9. DOI:
12. Trnka P. Henoch-Schönlein purpura in children. J Paediatr Child Health. 2013;49:995-1003. DOI:
13. Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C. Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. Pediatrics. 2007;120:1079-87. DOI:
14. Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, et al. Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006;149:241-7. DOI:
15. de Almeida JLJ, Campos LMA, Paim LB, Leone C, Koch VHK, Silva CAA. Kidney involvement in Henoch-Schönlein purpura: a multivariate analysis of initial prognostic factors. J Pediatr (Rio J). 2007;83:259-66. DOI:
16. Narchi H. Risk of long-term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005;90:916-20. DOI:
17. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Renal manifestations of Henoch-Schönlein purpura in a 6-month prospective study of 223 children. Arch Dis Child. 2010;95:877-82. DOI:
18. 18. Levin A, Stevens PE, Bilous RW, Coresh J, de Fransisco ALM, de Jong PE, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:5-14. DOI:
19. Ghrahani R, Ledika MA, Sapartini G, Setiabudiawan B. Age of onset as a risk factor of kidney involvement in Henoch-Schönlein purpura. Asia Pac Allergy. 2014;4:42-7. doi:10.5415/apallergy.2014.4.1.42
20. Sugianti I, Akib AA, Soedjatmiko S. Karakteristik purpura Henoch-Schönlein pada anak di Rumah Sakit Cipto Mangunkusumo. Sari Pediatr. 2016;16:128. DOI:
21. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626-38. DOI:
22. Hetland LE, Susrud KS, Lindahl KH, Bygum A. Henoch-Schönlein purpura: a literature review. Acta Derm Venereol. 2017;97:1160-6. DOI:
23. Chan H, Tang YL, Lv XH, Zhang GF, Wang M, Yang HP, et al. Risk factors associated with renal involvement in childhood Henoch-Schönlein purpura: a meta-analysis. PLoS One. 2016;11(11). DOI:
24. Fretzayas A, Sionti I, Moustaki M, Papadimitriou A, Nicolaidou P. Henoch-Schönlein purpura: a long-term prospective study in Greek children. J Clin Rheumatol. 2008;14:324-31. DOI:
25. Wang K, Sun X, Cao Y, Dai L, Sun F, Yu P, et al. Risk factors for kidney involvement and severe kidney disease in 2731 Chinese children with Henoch-Schönlein purpura: a retrospective study. Medicine (Baltimore). 2018;97:38(e12520). DOI:
26. Goldstein AR, White RH, Akuse R, Chantler C. Long-term follow-up of childhood Henoch-Schönlein nephritis. Lancet. 1992;339:280-2. DOI:
27. Rigante D, Candelli M, Federico G, Bartolozzi F, Porri MG, Stabile A. Predictive factors of kidney involvement or relapsing disease in children with Henoch-Schönlein purpura. Rheumatol Int. 2005;25:45-8. DOI:
28. Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8:345-50. DOI:
29. Park SJ, Suh JS, Lee JH, Lee JW, Kim SH, Han KH, et al. Advances in our understanding of the pathogenesis of Henoch-Schönlein purpura and the implications for improving its diagnosis. Expert Rev Clin Immunol. 2013;9:1223-38. DOI:
30. Nah EH, Kim S, Cho S, Cho HI. Complete blood count reference intervals and patterns of changes across pediatric, adult, and geriatric ages in Korea. Ann Lab Med. 2018;38:503-11. DOI:
31. Elmas AT, Tabel Y. Platelet counts in children with Henoch-Schonlein purpura-relationship to kidney involvement. J Clin Lab Anal. 2016;30:71-4. DOI:
32. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98:2720-5. DOI:
33. Yang M, Zhou M, Li SY, Chong B, Li XJ. IL-1? plays an important role on thrombocytosis in an immune vasculitis model via promoting megakaryopoiesis. Blood. 2013;122:2325. DOI:
34. Saulsbury FT, Kesler RW. Thrombocytosis in Henoch-Schönlein purpura. Clin Pediatr (Phila). 1983;22: 185–7. DOI:
35. Lin CY, Yang YH, Lee CC, Huang CL, Wang LC, Chiang BL. Thrombopoietin and interleukin-6 levels in Henoch-Schönlein purpura. J Microbiol Immunol Infect. 2006;39: 476-82.
36. Huber AM, King J, McLaine P, Klassen T, Pothos M. A randomized, placebo-controlled trial of prednisone in early Henoch-Schönlein purpura. BMC Med. 2004;2:7. DOI:
37. Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC. Interventions for preventing and treating kidney disease in Henoch-Schönlein purpura (HSP). Cochrane Database Syst Rev. 2009;3:CD005128. DOI:
How to Cite
Yanrismet Y, Hidayati E, Munasir Z, Yuliarti K, Fahriyani A. Incidence and risk factors of nephritis in childhood Henoch-Schonlein purpura. PI [Internet]. 28Aug.2023 [cited 21Jun.2024];63(4):304-4. Available from:
Pediatric Nephrology
Received 2021-10-26
Accepted 2023-08-28
Published 2023-08-28